Cargando…

Effectiveness and cost-effectiveness of combination therapy versus monotherapy in malignant melanoma

BACKGROUND: Until 2010, stage III or IV malignant melanoma (MM) had a poor prognosis. The discovery of immune checkpoint inhibitors (ICIs) in 2011 changed the treatment landscape. Promising results in patient survival with a checkpoint inhibitor prompted research into combination therapies. In 2016,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Özdemir, Dilay, Büssgen, Melanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521452/ https://www.ncbi.nlm.nih.gov/pubmed/37749653 http://dx.doi.org/10.1186/s40545-023-00611-7

Ejemplares similares

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Colistin monotherapy versus therapy combination
por: Charra, B, et al.
Publicado: (2010)

Severe complications of nivolumab monotherapy in an adolescent with malignant melanoma
por: Grzegorczyk, Aleksandra, et al.
Publicado: (2023)

Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain
por: Grau, Santiago, et al.
Publicado: (2016)

Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy
por: Pradeep, Jnaneshwari, et al.
Publicado: (2022)

Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension
por: Kim, Jae Hyun, et al.
Publicado: (2014)

Effectiveness of Topical Ganciclovir 2% Monotherapy Versus Combined Steroid Therapy in Cytomegalovirus Endotheliitis
por: Kuo, Yu-Wei, et al.
Publicado: (2022)

Diabetes Monotherapies versus Metformin-Based Combination Therapy for the Treatment of Type 2 Diabetes
por: Singh, Awadhesh K, et al.
Publicado: (2021)

Pipeline progress and portfolio management of the top 30 pharma companies over the past two decades
por: Büssgen, Melanie, et al.
Publicado: (2023)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Peng, Ye, et al.
Publicado: (2021)

PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research
por: Zhang, Yu, et al.
Publicado: (2021)

Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis
por: Mathis, Sandra, et al.
Publicado: (2011)

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma
por: Woo, Taylor E., et al.
Publicado: (2023)

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China
por: Gu, Shuyan, et al.
Publicado: (2016)

Effect and safety of combination lipid‐lowering therapies based on statin treatment versus statin monotherapies on patients with high risk of cardiovascular events
por: Wang, Chunli, et al.
Publicado: (2018)

Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn’s disease and ulcerative colitis
por: Hashash, Jana G., et al.
Publicado: (2021)

Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry
por: Mease, Philip J, et al.
Publicado: (2015)

Cost-effectiveness of glaucoma management with monotherapy medications in Egypt
por: El-Khamery, Amal Abd-Elaal, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM)
por: Garay, Osvaldo Ulises, et al.
Publicado: (2019)

Combination therapy versus monotherapy for EUS-guided management of gastric varices: A systematic review and meta-analysis
por: McCarty, Thomas R., et al.
Publicado: (2019)

PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis
por: Lin, Zhijuan, et al.
Publicado: (2016)

Arginine deprivation therapy for malignant melanoma
por: Yoon, Jung-Ki, et al.
Publicado: (2012)

Epigenetics in the Diagnosis and Therapy of Malignant Melanoma
por: Santourlidis, Simeon, et al.
Publicado: (2022)

The comparative study to evaluate the effect of palonosetron monotherapy versus palonosetron with dexamethasone combination therapy for prevention of postoperative nausea and vomiting
por: Park, Jung Woo, et al.
Publicado: (2012)

Cost Effectiveness of ACEIs/ARBs versus Amlodipine Monotherapies: A Single-Center Retrospective Chart Review
por: AlRuthia, Yazed, et al.
Publicado: (2021)

Current evidence for the treatment of hypothyroidism with levothyroxine/levotriiodothyronine combination therapy versus levothyroxine monotherapy
por: Hennessey, James V., et al.
Publicado: (2018)

1601. Combination Therapy versus Monotherapy for Carbapenem-resistant Organisms: Is More Really Better?
por: Najia, Laila, et al.
Publicado: (2020)

10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
por: Büssgen, Melanie, et al.
Publicado: (2023)

Does health technology assessment compromise access to pharmaceuticals?
por: Büssgen, Melanie, et al.
Publicado: (2023)

Indication-wide drug pricing: Insights from the pharma market
por: Siegmeier, Florian, et al.
Publicado: (2022)

Changes in launch delay and availability of pharmaceuticals in 30 European markets over the past two decades
por: Büssgen, Melanie, et al.
Publicado: (2022)

Does health technology assessment compromise access to pharmaceuticals?
por: Büssgen, Melanie, et al.
Publicado: (2022)

Anticancer effect of terpenes: focus on malignant melanoma
por: Wróblewska-Łuczka, Paula, et al.
Publicado: (2023)

Evaluating cost benefits of combination therapies for advanced melanoma
por: Jensen, Ivar S., et al.
Publicado: (2016)

Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis
por: Jiang, Guan, et al.
Publicado: (2014)

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
por: Taylor, Peter C., et al.
Publicado: (2022)

Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents
por: Khan, Mohammad K, et al.
Publicado: (2011)

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy
por: Dai, Jie, et al.
Publicado: (2023)

Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer
por: Peng, Jingyuan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0lacdbkmc29t64l9p801d85scd